Sutro Biopharma, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sutro Biopharma, Inc.
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
Public Company Edition: Private Galderma raised $1bn but said its next likely financing will be an IPO. Also, Azitra went public while Turnstone, Apogee and Sagimet initiated the process; Sutro signed a royalty deal for up to $390m; and despite a follow-on offering mini-surge, cost cuts continue.
The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.
It is ‘up in the air’ what manufacturers and the FDA will have to do if an appeals court does not stay the injunction against mifepristone. More than 400 biopharma industry leaders sign a letter calling for reversal of Judge Kacsmaryk’s order and supporting the FDA’s regulatory authority.
- Drug Discovery Tools
Drug Discovery Tools
- Molecular Diversity
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.